mind body glp 1 Dual-action obesity drug rewires brain circuits for appetite Daily GLP-1 Support – Midi

Von der Diabetes-Therapie zum Abnehmspritzen-Trend Die ersten Formen des Wirkstoffs wurden zunchst fr die Behandlung von Typ-2-Diabetes entwickelt, weil damit, wie weiter oben bereits beschrieben, der Blutzuckerspiegel reguliert werden kann

Extended clinical trials and real-world data are crucial to understand their lasting impact on weight, metabolic health, and potential side effects

J Pharmacol Exp Ther 306:347354

Epub 2023 Oct 10

Convergent evidence shows that (i) obesity is associated with reduced striatal D2 receptor availability [27], (ii) high-glycemic/rapid-absorption carbohydrates are plausible pharmacokinetic drivers of addictive-like responses [25], and (iii) ultra-processed foods high in refined carbohydrates and/or fat are disproportionately linked to addictive-like eating behaviors [28]

Two of the most significant risk factors for the development of MASLD are obesity and type 2 diabetes both of which are positively impacted by GLP1 receptor agonists and are FDA-approved indications for GLP1 receptor agonist utilization